Natera Zukünftiges Wachstum
Future Kriterienprüfungen 4/6
Natera wird ein jährliches Gewinn- und Umsatzwachstum von 62.4% bzw. 14.8% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 62.8% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 1.6% betragen.
Wichtige Informationen
62.4%
Wachstumsrate der Gewinne
62.75%
EPS-Wachstumsrate
| Biotechs Gewinnwachstum | 25.2% |
| Wachstumsrate der Einnahmen | 14.8% |
| Zukünftige Eigenkapitalrendite | 1.59% |
| Analystenabdeckung | Good |
| Zuletzt aktualisiert | 15 May 2026 |
Jüngste Aktualisierungen zum künftigen Wachstum
Recent updates
Analyseartikel • May 13
Analysts Have Made A Financial Statement On Natera, Inc.'s (NASDAQ:NTRA) First-Quarter Report
As you might know, Natera, Inc. ( NASDAQ:NTRA ) recently reported its quarterly numbers. Results overall were mixed...
Narrativ-Update • May 05
NTRA: MRD Leadership And New Genomic Offering Will Support Long-Term Trajectory
Analysts have kept their $300 price target on Natera unchanged, while slightly adjusting assumptions for discount rate, revenue growth, profit margins and future P/E after a mix of recent research that includes both modest target cuts and higher targets tied to updated models, guidance and a generally constructive view on the stock. Analyst Commentary Recent research paints a generally constructive picture of how Wall Street views Natera, with multiple bullish analysts fine tuning their models around updated guidance, P/E assumptions and profitability paths.
Narrativ-Update • Apr 20
NTRA: Oncology Execution And 2026 Catalysts Will Shape Fairly Valued Outlook
Analysts have trimmed the blended price target for Natera by about $2 to reflect updated models that incorporate slightly higher discount rates, revised revenue growth and profit margin assumptions, and a lower future P/E multiple, while still indicating constructive views from recent research coverage. Analyst Commentary Recent research on Natera presents a mix of supportive long term views and valuation recalibrations, with several firms updating models after quarterly results and competitive developments in genetic testing.
Narrativ-Update • Apr 05
NTRA: Molecular Residual Disease Leadership Will Drive Bullish Long Term Outlook
Analysts made a modest trim to the blended price target on Natera to about $259, reflecting slightly lower modeled revenue growth and profit margins. This adjustment comes even as several firms recently raised individual targets into the $215 to $300 range after updating their views on the company following Q4 results and new coverage initiations.Narrativ-Update • Mar 22
NTRA: Molecular Residual Disease Leadership And Genomics Launch Will Shape Future Outlook
The analyst fair value estimate for Natera has been adjusted modestly higher from $257.20 to $260.65, reflecting updated models that incorporate recent Street price target revisions and assumptions for revenue growth, profit margins, and future P/E multiples. Analyst Commentary Street research around Natera has centered on how the company executes on its current guidance, maintains its position in key testing markets, and justifies premium valuation multiples through future growth and margin delivery.Seeking Alpha • Mar 17
Natera Looks Compelling As Oncology Testing Momentum Keeps Building
Summary NTRA’s oncology franchise, led by Signatera MRD testing, is the main bull case at this point. As long as they keep building on their testing volumes, I believe this should support a long runway in cancer monitoring and recurrence detection. NTRA’s 2025 also included new product launches and added Medicare coverage, advanced early cancer detection, and broadened its molecular diagnostics portfolio. Their Foresight acquisition also strengthens NTRA’s MRD moat through PhasED-Seq technology, better testing sensitivity, and taps into lymphoma screening. I reckon NTRA’s valuation multiples are expensive. However, I think their current growth rate with Signatera justifies its price tag, which is why I lean bullish. Read the full article on Seeking AlphaNarrativ-Update • Mar 07
NTRA: Elevated Oncology And 2026 Catalyst Hopes Will Likely Cap Future Upside
The updated analyst price target for Natera edges higher to a fair value estimate of $208.44 from $194.59, reflecting recent Street research where several firms lifted their targets following Q4 results, improved gross margin commentary, and expectations for a catalyst rich 2026. Analyst Commentary Recent Street research on Natera points to a mixed backdrop, with a cluster of higher price targets sitting well above the updated fair value estimate of $208.44, but also some signs of restraint as models are refreshed after Q4 results and initial 2026 guidance.Narrativ-Update • Feb 21
NTRA: MRD Leadership And Broad Test Portfolio Will Support Long-Term Trajectory
Narrative Update on Natera Analysts have refreshed their views on Natera with price targets now reaching up to $300. This is supported by expectations for solid sector results, confidence in the company’s position across women's and organ health, and its growing role in the molecular residual disease market.Narrativ-Update • Feb 07
NTRA: Molecular Residual Disease Leadership And FDA Progress Will Shape Future Outlook
Analysts have raised their fair value estimate for Natera to about $257 from roughly $235, citing higher assumed revenue growth, improved profit margins, and Street research that highlights the company as an established diagnostics player with a strong position in molecular residual disease, along with multiple recent price target increases up to $300. Analyst Commentary Recent Street research has been broadly constructive on Natera, with several bullish analysts lifting their price targets and emphasizing the company’s role in diagnostics and molecular residual disease.Narrativ-Update • Jan 24
NTRA: Expanding MRD Adoption And New Data Will Support Long-Term Trajectory
Analysts have lifted their Natera price targets into a US$220 to US$300 range, citing recent earnings beats, raised estimates, and what they describe as strong fundamentals and a long growth runway across diagnostics and molecular residual disease testing. Analyst Commentary Recent Street research points to a cluster of higher Natera price targets, with several bullish analysts citing what they view as strong execution in diagnostics and molecular residual disease testing.Narrativ-Update • Jan 09
NTRA: Expanding MRD Adoption And Trials Will Support Long-Term Revenue Trajectory
Analysts have raised their fair value estimate for Natera to $300 from $285, citing a series of higher Street price targets and ongoing enthusiasm around the company's position in women's and organ health and the molecular residual disease market. Analyst Commentary Bullish analysts have been resetting their expectations higher, with a series of price target revisions in recent months that cluster in the US$210 to US$300 range.Narrativ-Update • Dec 26
NTRA: Expanding Oncology Diagnostics Will Drive Stronger Long-Term Revenue Trajectory
The analyst fair value estimate for Natera has been raised to $285 from $268, as analysts factor in stronger anticipated revenue growth and sustained momentum in key diagnostics franchises, reflected in a series of higher Street price targets. Analyst Commentary Bullish analysts have recently raised their price targets on Natera across the board, citing stronger than expected execution and a robust outlook for revenue growth.Narrativ-Update • Dec 12
NTRA: Elevated Expectations Around Oncology Expansion Will Likely Constrain Future Share Returns
Natera's analyst fair value estimate has been raised sharply from approximately $115 to about $195 per share, reflecting analysts' higher long term revenue growth assumptions and confidence following a series of recent price target increases across the Street. Analyst Commentary Recent Street research has been predominantly constructive on Natera, with multiple firms lifting price targets into the $200 to $280 range and reiterating positive ratings.Narrativ-Update • Nov 27
NTRA: Recent Clinical Results And Competitive Position Will Influence Future Outlook
Natera's analyst price target has been raised to $234.68 from $222.58. Analysts cite ongoing strong revenue performance, increased growth expectations, and recent research milestones as the primary drivers for the upward revision.Narrativ-Update • Nov 11
NTRA: Recent Clinical Results And Cash Flow Risks Will Shape Future Performance
Natera's analyst price target has increased significantly from $202.50 to $222.58. This reflects analysts' optimism following raised estimates and expectations for continued growth, in light of recent positive clinical trial updates and industry leadership.Narrativ-Update • Oct 27
Clinical Advances and AI Will Drive Expansion Into New Diagnostic Markets
Analysts raised their fair value estimate for Natera to $202.50 from $193.80. They cited momentum from recent clinical developments, positive trial updates, and ongoing strength in the company’s diagnostic and oncology business lines.Narrativ-Update • Sep 28
Molecular Diagnostics And AI Integration Will Unlock New Market Opportunities
Analysts lowered Natera’s price target modestly to $193.80 as continued optimism around its liquid biopsy leadership and growth opportunities was tempered by renewed concerns about elevated valuation and margin outlook. Analyst Commentary Bullish analysts note Natera's leadership in liquid biopsy testing and large addressable markets in prenatal, minimal residual disease, and potential cancer screening, supporting long-term double-digit revenue growth.Narrativ-Update • Sep 04
Molecular Diagnostics And AI Integration Will Unlock New Market Opportunities
Analysts raised Natera’s price target slightly to $198.45, citing strong Q2 results, continued leadership in liquid biopsy, robust pipeline momentum, and increasing market opportunities in cancer screening and prenatal testing. Analyst Commentary Bullish analysts cited Natera's solid Q2 beat, with significant revenue upside and sustained business momentum, leading to raised outlooks for 2025.Analyseartikel • Aug 31
Optimistic Investors Push Natera, Inc. (NASDAQ:NTRA) Shares Up 25% But Growth Is Lacking
Natera, Inc. ( NASDAQ:NTRA ) shares have had a really impressive month, gaining 25% after a shaky period beforehand...Analyseartikel • May 18
There's Reason For Concern Over Natera, Inc.'s (NASDAQ:NTRA) Price
Natera, Inc.'s ( NASDAQ:NTRA ) price-to-sales (or "P/S") ratio of 11.4x might make it look like a sell right now...Neues Narrativ • May 11
Signatera, Prospera And Renasight Will Transform Diagnostics
Strong revenue growth driven by increased diagnostic volumes and strategic partnerships positively impacts Natera's earnings and future revenue potential.Gewinn- und Umsatzwachstumsprognosen
| Datum | Umsatz | Gewinne | Freier Cashflow | Bargeld aus operativen Tätigkeiten | Durchschn. Anz. Analysten |
|---|---|---|---|---|---|
| 12/31/2028 | 3,955 | 203 | 255 | 739 | 13 |
| 12/31/2027 | 3,296 | -44 | 166 | 469 | 18 |
| 12/31/2026 | 2,791 | -219 | 115 | 262 | 18 |
| 3/31/2026 | 2,501 | -226 | 72 | 211 | N/A |
| 12/31/2025 | 2,306 | -208 | 76 | 215 | N/A |
| 9/30/2025 | 2,117 | -309 | 94 | 194 | N/A |
| 6/30/2025 | 1,964 | -253 | 105 | 187 | N/A |
| 3/31/2025 | 1,831 | -190 | 85 | 153 | N/A |
| 12/31/2024 | 1,697 | -190 | 59 | 136 | N/A |
| 9/30/2024 | 1,532 | -215 | -44 | 25 | N/A |
| 6/30/2024 | 1,361 | -292 | -118 | -56 | N/A |
| 3/31/2024 | 1,209 | -365 | -197 | -139 | N/A |
| 12/31/2023 | 1,083 | -435 | -286 | -247 | N/A |
| 9/30/2023 | 989 | -499 | -311 | -270 | N/A |
| 6/30/2023 | 931 | -512 | -387 | -343 | N/A |
| 3/31/2023 | 868 | -546 | -419 | -375 | N/A |
| 12/31/2022 | 820 | -548 | -479 | -432 | N/A |
| 9/30/2022 | 776 | -546 | -498 | -449 | N/A |
| 6/30/2022 | 723 | -576 | -492 | -438 | N/A |
| 3/31/2022 | 667 | -546 | -453 | -398 | N/A |
| 12/31/2021 | 625 | -472 | -385 | -335 | N/A |
| 9/30/2021 | 565 | -408 | -354 | -310 | N/A |
| 6/30/2021 | 505 | -315 | -280 | -252 | N/A |
| 3/31/2021 | 449 | -258 | -244 | -222 | N/A |
| 12/31/2020 | 391 | -230 | -202 | -183 | N/A |
| 9/30/2020 | 362 | -189 | -139 | -124 | N/A |
| 6/30/2020 | 342 | -153 | -117 | -104 | N/A |
| 3/31/2020 | 330 | -126 | -79 | -67 | N/A |
| 12/31/2019 | 302 | -125 | N/A | -63 | N/A |
| 9/30/2019 | 286 | -121 | N/A | -61 | N/A |
| 6/30/2019 | 273 | -128 | N/A | -72 | N/A |
| 3/31/2019 | 262 | -129 | N/A | -103 | N/A |
| 12/31/2018 | 258 | -128 | N/A | -71 | N/A |
| 9/30/2018 | 243 | -144 | N/A | -86 | N/A |
| 6/30/2018 | 233 | -142 | N/A | -94 | N/A |
| 3/31/2018 | 223 | -137 | N/A | -72 | N/A |
| 12/31/2017 | 210 | -138 | N/A | -98 | N/A |
| 9/30/2017 | 207 | -128 | N/A | -99 | N/A |
| 6/30/2017 | 205 | -126 | N/A | -92 | N/A |
| 3/31/2017 | 205 | -121 | N/A | -99 | N/A |
| 12/31/2016 | 213 | -100 | N/A | -74 | N/A |
| 9/30/2016 | 221 | -81 | N/A | -49 | N/A |
| 6/30/2016 | 212 | -72 | N/A | -42 | N/A |
| 3/31/2016 | 205 | -69 | N/A | -35 | N/A |
| 12/31/2015 | 190 | -70 | N/A | -38 | N/A |
| 9/30/2015 | 187 | -46 | N/A | -23 | N/A |
| 6/30/2015 | 189 | -28 | N/A | 0 | N/A |
Analystenprognosen zum zukünftigen Wachstum
Einkommen vs. Sparrate: NTRA wird in den nächsten 3 Jahren voraussichtlich rentabel werden, was als schnelleres Wachstum als die Sparquote angesehen wird (3.5%).
Ertrag vs. Markt: NTRA wird in den nächsten 3 Jahren voraussichtlich rentabel werden, was als überdurchschnittliches Marktwachstum angesehen wird.
Hohe Wachstumserträge: NTRA wird voraussichtlich in den nächsten 3 Jahren rentabel werden.
Einnahmen vs. Markt: NTRADie Einnahmen des Unternehmens (14.8% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (11.7% pro Jahr).
Hohe Wachstumseinnahmen: NTRADie Einnahmen des Unternehmens (14.8% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.
Wachstumsprognosen für den Gewinn je Aktie
Künftige Eigenkapitalrendite
Künftige Eigenkapitalrendite: NTRADie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich niedrig sein (1.6%).
Wachstumsunternehmen entdecken
Unternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/05/15 06:57 |
| Aktienkurs zum Tagesende | 2026/05/15 00:00 |
| Gewinne | 2026/03/31 |
| Jährliche Einnahmen | 2025/12/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Einzelheiten zu dem Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite. Außerdem bieten wir Leitfäden zur Verwendung unserer Berichte und Tutorials auf YouTube an.
Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
Natera, Inc. wird von 30 Analysten beobachtet. 18 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| Catherine Ramsey Schulte | Baird |
| Luke Sergott | Barclays |
| Raymond Myers | Benchmark Company |